thiazolyl blue has been researched along with Acrocephaly in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ang, BU; Kirschner, RE; Nah, HD; Spivak, RM | 1 |
Choi, JY; Kim, HJ; Kim, SY; Lee, MH; Lee, SW; Park, HS; Park, MH; Ryoo, HM; Shin, HI | 1 |
2 other study(ies) available for thiazolyl blue and Acrocephaly
Article | Year |
---|---|
Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
Topics: Acrocephalosyndactylia; Adenoviridae; Alkaline Phosphatase; Animals; Arginine; Biomarkers; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Coloring Agents; Core Binding Factor Alpha 1 Subunit; Craniofacial Dysostosis; Craniosynostoses; Cysteine; Dura Mater; Genetic Vectors; Mice; Osteoblasts; Osteogenesis; Osteopontin; Phenylalanine; Point Mutation; Receptor, Fibroblast Growth Factor, Type 2; Syndrome; Tetrazolium Salts; Thiazoles | 2010 |
Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure.
Topics: Amino Acid Motifs; Animals; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Nucleus; Cells, Cultured; Coloring Agents; Craniosynostoses; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblast Growth Factor 2; Flavonoids; Humans; In Situ Hybridization; Mice; Mitogen-Activated Protein Kinases; Oligonucleotides, Antisense; Osteoblasts; Osteopontin; Promoter Regions, Genetic; RNA; RNA, Messenger; Sialoglycoproteins; Signal Transduction; Tetrazolium Salts; Thiazoles; Time Factors; Transcription Factor AP-1 | 2003 |